Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: microtomographic, histological and immunohistochemical characterization
C. C. Biguetti, A. H. De Oliva, K. Healy, R. H. Mahmoud, I. D. C. Custodio, D. H. Constantino, E. Ervolino, M. A. H. Duarte, W. D. Fakhouri, M. A. Matsumoto
Abstract
Treatment with cumulative dosages of zoledronic acid (ZA) in elderly patients is a risk factor for the development of medication-related osteonecrosis of the jaws (MRONJ), mainly related to surgical triggers such as tooth extraction. However, animal models for the investigation and understanding of MRONJ pathophysiology in senescent and postmenopausal stages remains to be developed and characterized. The aim of this study was to analyze MRONJ development in senescent female mice treated with cumulative dosages of ZA. For this purpose, twenty 129/Sv female mice, 64 weeks old, were treated with 0.9% saline solution as Control group (n=10), and with ZA at 250{micro}g/Kg (n=10), once a week, starting 4 weeks before the upper right incisor extraction and until the end of the experimental time points (7 days and 21 days). At 7 and 21 days, specimens were harvested for microCT, histological, birefringence and immunohistochemical analysis. Clinically, an incomplete epithelialization was observed in ZA group at 7 days and a delayed bone matrix mineralization and collagen maturation at 7 and 21 days compared to the controls. Controls revealed sockets filled with mature bone at 21 days as observed by microCT and birefringence, while ZA group presented delayed bone deposition at 7 and 21 days, as well increased leukocyte infiltration and blood clot at 7 days, and increased bone sequestrum and empty osteocyte lacunae at 21 days (p<0.05). Also, ZA group presented decreased quantity TGFb+ and Runx-2+ cells at 7 days, and decreased quantity of TRAP+ osteoclasts compared to the control at 21 days (p<0.05). Togheter, these data demonstrate the usefulness of this model to understanding the pathophysiology of MRONJ.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Protocol for standardized minimally invasive mouse models of bisphosphonate-related and radiation-induced jaw osteonecrosis
Zhangfan Ding, 张家源, … Junyu Chen·STAR ProtocolsPeer-reviewed·Oct 5, 2026
- Zoledronate reduces loading-induced microdamage in cortical ulna of ovariectomized rats
B. Ning, I. Londono, … I. Villemure·bioRxiv·May 12, 2023
- In vitro and in vivo effects of zoledronate on senescence and senescence-associated secretory phenotype markers
P. Samakkarnthai, D. Saul, … S. Khosla·AgingPeer-reviewed·May 7, 2023
- Zoledronic acid improves bone quality and muscle function in a high bone turnover state
T. Trivedi, M. Manaa, … T. A. Guise·bioRxiv·Jun 1, 2023
- Single-cell RNA sequencing reveals collagen interactions between detached osteoclasts and activated fibroblasts in granulation tissue surrounding sequestra in medication-related osteonecrosis of the jaw
Chika Nakanishi, Takeshi Yoshida, … Masaya Akashi·bioRxiv·Feb 2, 2026
- Low-Magnitude Mechanical Signals Combined with Zoledronic Acid Reduce Musculoskeletal Weakness and Adiposity in Estrogen-Deprived Mice
G. M. Pagnotti, T. Trivedi, … T. A. Guise·bioRxiv·Mar 12, 2023